Determination of the median effective dose of dexmedetomidine for the prevention of emergence agitation in geriatric patients undergoing major open surgery with general anesthesia: A prospective, double-blinded, dose-response trial

weibing wang  
Department of Anesthesiology, The Affiliated Anqing Municipal Hospital of Anhui Medical University  
https://orcid.org/0000-0002-6059-7916

AiJiao Sun (✉️ 1011356643@qq.com)  
The affiliated AnQing municipal hospitals of Anhui Medical University

JingBo Xiao  
Anhui Medical University

JingChun Dong  
Anhui Medical University

Huang Xu  
Anhui Medical University

Hui Zhou  
Anhui Medical University

---

Research article

**Keywords:** Dexmedetomidine, Emergence agitation, Median effective dose, Geriatric

**DOI:** https://doi.org/10.21203/rs.3.rs-152373/v1

License: 😊 This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

Background

Dexmedetomidine can effectively decrease the incidences of emergence agitation (EA) in adult patients, but there are major side effects related to increased dose of dexmedetomidine. The purpose of this study was to determine of the median effective dose of dexmedetomidine in the prevention of EA among geriatric patients undergoing major open surgery with general anesthesia.

Methods

A total of 50 geriatric patients were enrolled in this study. Dexmedetomidine 0.5µg·kg⁻¹·h⁻¹ continuous intravenous infusion was administered to the first patient. The next dose was increased or decreased by 0.05 depending on the response of the previous patient, according to the Dixon up-and-down method. An “effective” or “ineffective” response was determined based on the Riker sedation-agitation score (RSAS), we defined “effective” as RSAS < 5, and “ineffective” as RSAS ≥ 5.

Results

The ED50 of dexmedetomidine in prevention of EA was 0.30µg·kg⁻¹·h⁻¹ (95% CI, 0.27–0.33) and the predicted ED95 was 0.42µg·kg⁻¹·h⁻¹ (95% CI, 0.38–0.51). The incidence of bradycardia was significantly increased in group without EA compared to the group with EA (57.1% vs 13.6%, P = 0.002).

Conclusions

The ED50 of dexmedetomidine in prevention of EA was 0.30µg·kg⁻¹·h⁻¹ (95% CI, 0.27–0.33) and the predicted ED95 was 0.42µg·kg⁻¹·h⁻¹ (95% CI, 0.38–0.51). Bradycardia was the main complication.

Trial registration

This study was registered in the Chinese Clinical Trial Registry (Registration number: ChiCTR1900023769) on June 11th, 2019.

Background

Post-anesthesia emergence agitation (EA) was first described by Eckenhoff in 1961. EA was first characterized as confusion, agitation, disorientation, and hallucinations during emergence from general anesthesia.[1] EA usually occurs during the initial 30 and 60 min in recovery from general anesthesia, and it may last from 45 min to 48 h in some patients.[2] The incidences of EA in adults has been reported to differ according to the variability of surgery, patient population, and the methods used to assess EA. The incidence of EA ranges from 3.7% to 30%, and its incidence is also associated with the use of a urinary catheter or an endotracheal tube and with postoperative pain.[3,4,5,6]
The risk factors for EA and measures to prevent EA in adult patients are unclear and still being studied. Factors that are significantly related to EA include having an endotracheal tube, urinary catheter, postoperative pain (numerical rating scale, NRS ≥ 5), anesthesia based on inhalation, smoking history and younger age.[7,8] Although the etiology of EA is not clear, because of the different recovery rate in different brain areas, inhalational agents with higher incidence of EA may explain why, less soluble agents have faster recovery from general anesthesia.[9]

Dexmedetomidine is an alpha 2 adrenoreceptor agonist with analgesia, sedation, ant-anxiety, and stress-relief effects, and it may be effective in preventing EA due to dexmedetomidine excitement of the central alpha 2 receptors in the locus coeruleus.[10,11]

Dexmedetomidine is a recently developed drug, it has been widely used to prevent postoperative EA in children, and it effectively reduces EA incidence without side effects.[12,13,14] Many recent studies have demonstrated that intraoperative dexmedetomidine infusion also decreases the incidence of EA in adult patients but has side effects including intraoperative hypotension and bradycardia.[15,16] However, different doses have been examined in different studies,[17,18] so there is no consensus on the appropriate dose of dexmedetomidine in geriatric patients to prevent EA. Therefore, it is necessary to identify the safe dose range for dexmedetomidine to effectively prevent EA and avoid drug side effects.

**Methods**

The aim

We conducted a prospective, double-blinded, dose-response trial. The primary study outcome was to optimize the median effective dose (ED50) of dexmedetomidine for the prevention of EA in geriatric patients undergoing major surgery with general anesthesia. The secondary outcomes included changes of mean arterial pressure (MAP), heart rate (HR), NRS of pain after extubation, and incidence of bradycardia.

Design and setting

A total of 50 geriatric patients (age ≥ 70 years) with an American Society of Anesthesiologists (ASA) physical status I or II and undergoing major open surgery were enrolled in this study. The medical ethical committees of AnQing Municipal Hospital of Anhui Medical University approved this study (Approval date: 20, December , 2018 ), and the study was registered in the Chinese Clinical Trial Registry (Registration number:ChiCTR1900023769). All patients provided written informed consent.

The exclusion criteria are as follows: hypotension, hypertension, bradycardia, tachycardia, arrhythmia, pre-existing cardiopulmonary disease or mental health problems, renal or hepatic functional abnormalities.

Materials
All patients were transported to the operating theatre, where they were subjected to standard monitoring electrocardiography, HR, pulse oximetry and bispectral index (BIS). A catheter was inserted into the radial artery under local anesthesia with 1% lidocaine to continuously monitor MAP.

Intravenous etomidate (Enhua pharmaceutical CO. Ltd. JiangSu, China.) 0.25 mg·kg⁻¹, sufentanil (Renfu pharmaceutical CO. Ltd. HuBei, China.) 0.5 μg·kg⁻¹, and cisatracurium (Hengrui pharmaceutical CO. Ltd. JiangSu, China.) 0.2 mg·kg⁻¹, were administered for anesthesia induction; then propofol (Yangsen pharmaceutical CO. Ltd. XiAn, China.) 3~6 mg·kg⁻¹·h⁻¹ and remifentanil (Renfu pharmaceutical CO. Ltd. HuBei, China.) 0.1~0.2 μg·kg⁻¹·min⁻¹ were administered for anesthesia maintenance with a BIS between 40 and 60 during surgery. Patients were sent back to post-anesthesia care unit (PACU) at the end of the surgery.

Dexmedetomidine (Enhua pharmaceutical CO. Ltd. JiangSu, China.) 0.5 μg·kg⁻¹·h⁻¹ continuous intravenous infusion was administered to the first patient after intubation, and the infusion was stopped at the end of the surgery. The next dose was increased or decreased by 0.05 depending on the response of the previous patient, according to the Dixon up-and-down method. An “effective” or “ineffective” response was determined based on the Riker sedation-agitation score (RSAS), we defined “effective” as the RSAS < 5, and “ineffective” as the RSAS ≥ 5.

The EA was assessed by the RSAS and the RSAS is shown in Table 1. EA was defined as an RSAS ≥ 5 after extubation in the PACU.[19]

Measurements

MAP and HR were monitored every 5 min during surgery and in the PACU until the end of the study.

Emergence is defined as the interval within 2 minutes after extubation. The RSAS was assessed by an independent anesthesia assistant who was blinded to the dose of dexmedetomidine in this study, and another anesthesia nurse blinded to the dose assessed pain intensity by the NRS (Patients described their pain intensity on a number from 0 to 10, the higher scores represent the worse pain) at the time point of extubation, and 5 min, 10 min, 15 min, 30 min after extubation in the PACU. Rescue analgesics, such as flurbiprofen axetil, tramadol and opioids were intravenously administered when the NRS ≥ 5.

A 20% decrease in MAP compared with the baseline triggered administration of 5 to 10 mg intravenous ephedrine, and a decrease in HR of less than 45 beats·min⁻¹ 0.5 mg triggered administration of intravenous atropine.

Statistics

At least six “effective-ineffective” pairs were required for statistical analysis according to Dixon's up-and-down method.; therefore, patient enrolment continued until six crossover pairs were observed.[20] There were nine “effective-ineffective” pairs in our study, so the sample size is sufficient.
The average of all “effective-ineffective” pairs was used to calculate ED50 using Dixon’s up-and-down method. The number of responders at each dose was used to plot a sigmoid dose-response curve. Probit regression was performed and the interpolation was used to obtain ED50 and ED95.

The various parameters were statistically analysed using the SPSS 17.0 (SPSS Inc., Chicago, IL, USA). Parametric data were evaluated with independent samples t-test, and frequency data with Chi square test. P<0.05 was considered statistically significant.

**Results**

Fifty-eight patients were enrolled in this study. Three patients did not consented to participate and five patients were excluded from this study. The participants' flow during the study is shown in Figure 1.

The consecutive patients receiving dexmedetomidine using Dixon's up-and-down method are shown in Figure 2. Twenty-two patients manifested with EA and, twenty-eight patients did not have EA.

Demographic characteristics of all patients are shown in Table 2. The time to extubation was not prolonged in the group without EA compared to the group with EA.

The ED50 of dexmedetomidine in the prevention of EA among geriatric patients was 0.32 μg·kg⁻¹·h⁻¹ (95% CI, 0.26–0.38) according to Dixon's up-and-down method. A dose-response curve was plotted by probit analysis and shown in Figure 3. Logistic regression analysis of the dose-response curve and confirmed that the ED50 of dexmedetomidine for the prevention of EA in geriatric patients was 0.30 μg·kg⁻¹·h⁻¹ (95% CI, 0.27–0.33) and the ED95 was 0.42 μg·kg⁻¹·h⁻¹ (95% CI, 0.38–0.51).

The changes of MAP, HR and NRS of pain are shown in Figure 4 A,B and C.

There are sixteen patients manifested bradycardia in the group without EA and only three in the group with EA, the incidence of bradycardia was significantly increased in the group without EA compared to the group with EA(57.1% vs 13.6%, P=0.002), Figure 4D.

**Discussion**

The results of our dose-response study show that the ED50 and ED95 of dexmedetomidine for the prevention of EA in geriatric patients are 0.30μg·kg⁻¹·h⁻¹ and 0.42μg·kg⁻¹·h⁻¹, respectively. No patient suffered any majorcomplication, such as residual sedation, respiratory depression, or delay in extubation. There were 22 patients with EA and 28 patients without EA, and there was no significant difference in demographic characteristics (Table 2) between the two groups.

Dexmedetomidine is a highly selective alpha 2 adrenoreceptor agonist with a short half-life. It is used to prevent EA in adult patients in recently years. A bolus dose (range from 0.25μg·kg⁻¹ to 1.0μg·kg⁻¹) or continuous infusion (0.4μg·kg⁻¹·h⁻¹) of dexmedetomidine can reduce EA in adults after general anesthesia
but was associated with increased hypotension, delayed extubation, residual sedation, and prolonged PACU stay.[21,18] It is important to optimize the dose of dexmedetomidine to prevent EA and decrease complications in geriatric patients. We report the ED50 and ED95, determined using Dixon’s up-and-down method, as well as the effective dose of dexmedetomidine for the prevention of EA in order to decrease complications related to an excessive dose of dexmedetomidine.

Using Dixon’s up-and-down method to estimate the ED50, it requires a small sample size and relatively accurate results. Tracheal intubation increases the risk of EA by approximately fivefold, and postoperative pain of NRS ≥5 doubled the risk of EA.[7] Various studies have reported on different doses of dexmedetomidine for prevention of EA. A retrospective cohort study showed that dexmedetomidine continuous infusion at a rate of 0.2–0.7 µg kg\(^{-1}\) h\(^{-1}\), and suggested that dexmedetomidine decreased the incidence of EA, but bradycardia was a main side effect.[22] Considering the use of tracheal intubation and the high level of postoperative pain after major open surgery in geriatric patients, we selected 0.5 µg·kg\(^{-1}\)·h\(^{-1}\) of dexmedetomidine as the initial dose. Kim HS et al selected a dosing increment of dexmedetomidine of 0.1 in children.[23] We used this increment in our preliminary study, but it was inappropriate for geriatric patients because of their great differences in haemodynamics. Thus, we selected 0.05 as the dosing increment of dexmedetomidine.

The dose of dexmedetomidine is a critical factor for maintaining MAP. Hals S et al demonstrated that premedication with 1.0 µg·kg\(^{-1}\) oral dexmedetomidine decreases the MAP more than 25% compared with a 0.5 µg·kg\(^{-1}\) dose and saline placebo. [24] In our study, the dose does not reduce MAP and HR in the group without EA, on the contrary, the MAP and HR were significantly increased in the group with EA(Figure 4A,B) because of the increased NRS (Figure 4C). The ED50 not only decreased EA but also maintained MAP and HR stability in geriatric patients.

While the efficacy of midazolam and dexmedetomidine intravenous infusion were comparable in the prevention of EA during short and simple surgery (mean duration of surgery 87±44 min),[25] in another study with more complex surgery (mean duration of surgery more than 120min), the incidences of EA was significantly lower in the group treated with dexmedetomidine, and complications—such as depth of sedation, hypotension, and respiratory depression—were higher in the group treated with midazolam.[26] In our major open surgery(mean duration of surgery 249±40min,Table 2), dexmedetomidine appeared to effectively prevent EA in geriatric patients without any complications.

There are many studies confirmed that dexmedetomidine causes bradycardia when used for the prevention of EA in geriatric patients. A meta-analysis including 842 participants come from 12 randomized controlled trials shown that dexmedetomidine can effectively prevents EA, and has no significant reduction in the incidence of bradycardia[27]. A single study[17] and a retrospective cohort study (including 814 patients with intraoperative dexmedetomidine infusion) revealed a lower incidence of EA, and bradycardia was the main side effect.[28] Another meta-analysis including 10 trials and 1387 patients demonstrated that dexmedetomidine decreased the incidence of delirium in patients after cardiac surgery, but the incidence of bradycardia were increased. [29] Our study contained 3 patients with
bradycardia in the group with EA and 16 patients with bradycardia in group without EA (57.1% vs 13.6%, P=0.002, Figure 4D). We suggest that the optimal dose of dexmedetomidine should be reduced with the advancing of age, especially in geriatric patients. We should pay more attention to the incidence of bradycardia when dexmedetomidine infusion is administered to prevent EA among geriatric patients undergoing major open surgery.

There are two limitations to our study. The first is that the ED95 was predicted by probit regression. This method is not reliable for calculating the small percentage points of ED95 according to the Dixon up-and-down method, therefore, it is an inaccurate prediction, but it is well accepted. Although probit analysis may not be the best method, it is generally used to calculate the ED95 when the Dixon up-and-down method is used.[30,31] Another limitation of the study is the absence of a control group. We compared the incidence of bradycardia only between the group with EA and the group without EA, and the sample size was too small.

**Conclusions**

This study demonstrates that the ED50 of intravenous dexmedetomidine infusion in the prevention of EA among geriatric patients undergoing major open surgery was 0.30µg·kg⁻¹·h⁻¹ (95% CI, 0.27–0.33) and the predicted ED95 was 0.42µg·kg⁻¹·h⁻¹ (95% CI, 0.38–0.51). Bradycardia was the main complication.

**Abbreviations**

ED50 Median effective dose  
EA Emergence agitation  
NRS Numerical rating scale,  
MAP Mean arterial blood pressure  
HR Heart rate  
BIS Bispectral index  
RSAS Riker sedation-agitation score  
PACU Post-anesthesia care unit  

** Declarations**

**Ethics approval and consent to participate**

The study was approved by the medical ethical committees of AnQing municipal hospital of Anhui Medical University, China(No,2017-12-26). All patients gave written informed consent.
Consent for publication

Not applicable.

Availability of data and materials

The datasets collected and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding

The authors have received no specific grant from any funding agency in the public.

Authors’ contributions

WBW and AJS conceived the study and its design, acquisition of data by JBX and JCD, drafting of the article and critical revision by HZ and HX, and all authors have read and approved the manuscript.

Acknowledgements The authors would like to thank all staff members in the Department of anesthesia and operating room of AnQing Municipal Hospitals of Anhui Medical University. The authors sincerely thank AiJiaoSun,M.D for his contributions to the dose-response trial design and his assistance with the study. The authors acknowledge Miss. Hui Zhou, who performed data extraction, and Dr. JingChun Dong and Dr. HuangXu, who helped review the study design and date analysis.

Authors’ information

Affiliations

Department of Anesthesiology, The affiliated AnQing municipal hospitals of Anhui Medical University, AnQing, AnHui province, China.

Declaration of Conflicting Interests

The authors declare that they have no conflicting interests.

Funding acknowledgment

The authors have received no specific grant from any funding agency in the public.

References
[1] Eckenhoff JE, Kneale DH, Dripps RD. The incidence and etiology of postanesthetic excitement: a clinical survey. Anesthesiology. 1961;22:667-673.

[2] Vlajkovic GP, Sindjelic RP. Emergence delirium in children: Many questions, few answers. Anesth Analg. 2007;104:84–91.

[3] Munk L, Andersen G, Møller AM. Post-anaesthetic emergence delirium in adults: incidence, predictors and consequences. Acta Anaesthesiol Scand. 2016;60(8):1059–1066.

[4] Lepousé C, Lautner CA, Liu L, Gomis P, Leon A. Emergence delirium in adults in the post-anaesthesia care unit. Br J Anaesth. 2006;96(6):747–753.

[5] Yu D, Chai W, Sun X, Yao L. Emergence agitation in adults: risk factors in 2,000 patients. Can J Anesth. 2010;57(9):843–848.

[6] Card E, Pandharipande P, Tomes C. Emergence from general anaesthesia and evolution of delirium signs in the post-anaesthesia care unit. Br J Anaesth. 2015;115(3):411–417.

[7] Hyo-Jin Kim, Duk-Kyung Kim, Hyo-Yeol Kim, Jin-Kyoung Kim, and Seung-Won Choi. Risk Factors of Emergence Agitation in Adults Undergoing General Anesthesia for Nasal Surgery. Clin Exp Otorhinolaryngol. 2015 Mar; 8(1): 46–51.

[8] Jun-Young Jo, MD, MS, Kyeo-Woon Jung, MD, MS, Ha-Jung Kim, MD, PhD, Se-Ung Park, MD, MS, Hanwool Park, MD, PhD, Seungwoo Ku, MD, PhD, and Seong-Soo Choi, MD, PhD. Effect of Total Intravenous Anesthesia vs Volatile Induction With Maintenance Anesthesia on Emergence Agitation After Nasal Surgery: A Randomized Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2019 Feb; 145(2): 117–123.

[9] Aouad MT, Nasr VG. Emergence agitation in children: An update. Curr Opin Anaesthesiol. 2005;18:614–9.

[10] Gerlach AT, Dasta JF. Dexmedetomidine: An updated review. Ann Pharmacother. 2007;41:245–52.

[11] Guo TZ, Jiang JY, Buttermann AE, Maze M. Dexmedetomidine injection into the locus ceruleus produces antinociception. Anesthesiology. 1996;84:873–81.

[12] Lin Y, Chen Y, Huang J, Chen H, Shen W, Guo W, Chen Q, Ling H, Gan X. Efficacy of premedication with intranasal dexmedetomidine on inhalational induction and postoperative emergence agitation in pediatric undergoing cataract surgery with sevoflurane. J Clin Anesth. 2016 Sep;33:289-95.

[13] Hauber JA1, Davis PJ, Bendel LP, Martyn SV, McCarthy DL, Evans MC, Cladis FP, Cunningham S, Lang RS, Campbell NF, Tuchman JB, Young MC. Dexmedetomidine as a Rapid Bolus for Treatment and Prophylactic Prevention of Emergence Agitation in Anesthetized Children. Anesth Analg. 2015 Nov;121(5):1308-15.
[14] Mukherjee A1, Das A2, Basunia SR3, Chattopadhyay S2, Kundu R3, Bhattacharyya R2. Emergence agitation prevention in paediatric ambulatory surgery: A comparison between intranasal Dexmedetomidine and Clonidine. J Res Pharm Pract. 2015 Jan-Mar;4(1):24-30.

[15] Pranjali Kurhekar, Krishnagopal Vinod, Buddhan Rajarathinam, J Shesa Dhiviya Krishna, and M. S. Raghuraman. Randomized comparison between dexmedetomidine and midazolam for prevention of emergence agitation after nasal surgeries. Saudi J Anaesth. 2018 Jan-Mar; 12(1): 61–66.

[16] Jakob SM, Ruokonen E, Grounds RM, Sarapohja T, Garratt C, Pocock SJ, Bratty JR, Takala J. Dexmedetomidine vs midazolam or propofol for sedation during prolonged mechanical ventilation: two randomized controlled trials. JAMA. 2012 Mar 21;307(11):1151-60.

[17] Sun Q, Wang X, Shi C, Li T, Jiang M, Qu H, Ma J. Consciousness inhibition of intravenous dexmedetomidine in patients undergoing lower limb surgery with epidural anesthesia: A dose-response study by age group. Pak J Pharm Sci. 2018 Nov;31(6(Special)):2863-2868.

[18] Akaansha Garg, Manoj Kamal, Sadik Mohammed, Geeta Singariya, Dilip S Chouhan, and Ghanshyam Biyani. Efficacy of dexmedetomidine for prevention of emergence agitation in patients posted for nasal surgery under desflurane anaesthesia: A prospective double-blinded randomised controlled trial. Indian J Anaesth. 2018 Jul; 62(7): 524–530.

[19] Riker RR, Picard JT, Fraser GL. Prospective evaluation of the Sedation-Agitation scale for adult critically ill patients. Crit Care Med. 1999;27(7):1325–1329.

[20] Dixon WJ, Massey FJ. Introduction to statistical analysis. 4th ed. New York: McGraw-Hill; 1983. pp. 428–39.

[21] Aouad MT, Zeeni C1, A Nawwar R, Siddik-Sayyid SM, Barakat HB, Elias S, Yazbeck Karam VG. Dexmedetomidine for improved quality of emergence from general anesthesia: A dose-finding study. Anesth Analg. 2019 Dec;129(6):1504-1511.

[22] Xianhui Kang, Xiaodong Tang, Yang Yu, Fangping Bao, Shuyuan Gan, Wei Zheng, Jian Zhang, and Shengmei Zhu. Intraoperative dexmedetomidine infusion is associated with reduced emergence agitation and improved recovery profiles after lung surgery: a retrospective cohort study. Drug Des Devel Ther. 2019; 13: 871–879.

[23] Kim HS, Byon HJ, Kim JE, Park YH, Lee JH, Kim JT. Appropriate dose of dexmedetomidine for the prevention of emergence agitation after desflurane anesthesia for tonsillectomy or adenoidectomy in children: up and down sequential allocation. BMC Anesthesiol. 2015 May 27;15:79.

[24] Abdel-Ghaffar HS1, Abdel-Wahab AH2, Roushdy MM. Oral trans-mucosal dexmedetomidine for controlling of emergence agitation in children undergoing tonsillectomy: a randomized controlled trial. Rev Bras Anestesiol. 2019 Sep - Oct;69(5):469-476.
[25] Pranjali Kurhekar, Krishnagopal Vinod, Buddhan Rajarathinam, J Shesha Dhiviya Krishna, and M. S. Raghuraman. Randomized comparison between dexmedetomidine and midazolam for prevention of emergence agitation after nasal surgeries. Saudi J Anaesth. 2018 Jan-Mar; 12(1): 61–66.

[26] Silva-Jr JM, Katayama HT, Nogueira FAM, Moura TB, Alves TL, de Oliveira BW. Comparison of dexmedetomidine and benzodiazepine for intraoperative sedation in elderly patients: a randomized clinical trial. Reg Anesth Pain Med. 2019 Mar;44(3):319-324.

[27] Jian Zhang, Yang Yu, Shuai Miao, Lu Liu, Shuyuan Gan, Xianhui Kang, Shengmei Zhu. Effects of peri-operative intravenous administration of dexmedetomidine on emergence agitation after general anesthesia in adults: a meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2019; 13: 2853–2864.

[28] Kang X, Tang X, Yu Y, Bao F, Gan S, Zheng W, Zhang J, Zhu S. Intraoperative dexmedetomidine infusion is associated with reduced emergence agitation and improved recovery profiles after lung surgery: a retrospective cohort study. Drug Des Devel Ther. 2019 Mar 12;13:871-879.

[29] Wu M, Liang Y, Dai Z, Wang S. Perioperative dexmedetomidine reduces delirium after cardiac surgery: A meta-analysis of randomized controlled trials. J Clin Anesth. 2018 Nov;50:33-42.

[30] Makkar JK, Ghai B, Wig J. Minimum alveolar concentration of desflurane with caudal analgesia for laryngeal mask airway removal in anesthetized children. Paediatr Anaesth. 2013;23:1010–4.

[31] Lee JR, Lee YS, Kim CS, Kim SD, Kim HS. A comparison of the end-tidal sevoflurane concentration for removal of the laryngeal mask airway and laryngeal tube in anesthetized children. Anesth Analg. 2008;106:1122–5.

Tables

Table 1 Riker sedation-agitation score of EA
| Score | State               | Behaviour                                           |
|-------|---------------------|-----------------------------------------------------|
| 1     | Unarousable         | Minimal or no response to noxious stimuli           |
| 2     | Very sedated        | Aroused to physical stimuli but does not follow commands |
| 3     | Sedated             | Difficult to arouse but awakens to verbal stimuli or gentle shaking |
| 4     | Calm and cooperative| Awakens easily, follows commands                    |
| 5     | Agitated            | Anxious or mildly agitated, calms down to verbal instructions |
| 6     | Very agitated       | Requires physical restraint and frequent verbal limits |
| 7     | Dangerous agitation | Trying to remove catheters, climbing over bedrail, or striking at staff |

Table 2: Demographic characteristics, ASA status, BIS, types of surgery, time to extubation, and duration of surgery.

|                         | Group with n=22 | Group without n=28 | EA | P value |
|-------------------------|-----------------|---------------------|----|---------|
| Age (years)             | 77±5            | 77±4.5              |    | 0.802Δ  |
| Height (cm)             | 164±7           | 167±9               |    | 0.258Δ  |
| Weight (kg)             | 64±11           | 68±10               |    | 0.245Δ  |
| Gender (M/F)            | 9/13            | 13/15               |    | 0.696※  |
| ASA (I / II)            | 16/6            | 20/8                |    | 0.919※  |
| BIS                     | 51±4            | 51±5                |    | 0.924Δ  |
| Types of surgery        |                 |                     |    |         |
| Thoracic/Abdominal      | 7/15            | 12/16               |    | 0.425※  |
| Time of extubation (min) | 39±10           | 40±11               |    | 0.828Δ  |
| Duration of surgery (min)| 249±40          | 256±45              |    | 0.566Δ  |

Data are presented as the mean ± SD or the number. Δ P-value: Student t test. ※ P-value: Chi-square test. M: male, F: female. Time to extubation was defined as the time interval between the end of anesthesia and extubation. BIS: bispectral index. ASA: American Society of Anesthesiologists.